NICE says no to Celgene's myeloma drug Imnovid; Sucampo, Takeda extend Amitiza pact;

> The U.K.'s cost-effectiveness watchdog has issued preliminary draft guidance not recommending Celgene's ($CELG) multiple myeloma treatment Imnovid. More

> Sucampo and Takeda have extended their licensing agreement for constipation drug Amitiza. Release

> ViiV Healthcare has won approval for HIV pill Triumeq in Canada. Release

> Scotland has recommended Novartis' ($NVS) Gilenya for patients with a severe form of relapsing multiple sclerosis. Report

> Retrophin has agreed to divest ketamine, Syntocinon Nasal Spray, and Vecamyl to Turing Pharmaceuticals. Release

And Finally... Pfizer ($PFE) has joined up with leaders in the breast cancer community to expand the breast cancer dialogue to include metastatic breast cancer. More

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?